Table 2.
Factors associated with treatment approach.
| Characteristic | Overall |
|---|---|
| No. (Column%) | |
| Sex | |
| Male | 528 (59.9%) |
| Female | 353 (40.1%) |
| Age at Diagnosis | |
| <50 yrs | 323 (36.7%) |
| 50–64 yrs | 355 (40.3%) |
| 65–79 yrs | 176 (19.9%) |
| 80 yrs or more | 27 (3.1%) |
| Race | |
| White | 770 (87.4%) |
| Black | 37 (4.2%) |
| Other | 74 (9.4%) |
| Insurance | |
| Private | 628 (71.4%) |
| Uninsured | 25 (2.8%) |
| Government | 215 (24.4%) |
| Unknown | 13 (1.5%) |
| Hospital Type | |
| Academic/NCI CC | 565 (64.0%) |
| Community | 24 (2.8%) |
| Comp Community | 159 (18.0%) |
| Other/Unknown | 134 (15.2%) |
| Hospital Volume | |
| Low: 1–2 | 285 (32.4%) |
| Medium: 2–10 | 345 (39.2 %) |
| High: >10 | 251 (28.4%) |
| Charles-Deyo Cormibidity Score | |
| 0 | 765 (86.9%) |
| 1 | 96 (10.9%) |
| 2 | 16 (1.8%) |
| 3 | 4 (0.4%) |
| Kadish | |
| A | 193 (21.9%) |
| B | 118 (13.4%) |
| C | 488 (55.4%) |
| D | 82 (9.3%) |
| T-Stage | |
| 1 | 193 (21.9%) |
| 2 | 94 (10.7%) |
| 3 | 202 (22.9%) |
| 4a | 127 (14.4%) |
| 4b | 265 (30.1%) |
| Dulguerov T- Stage | |
| 1 | 317 (36.0%) |
| 2 | 186 (21.1%) |
| 3 | 140 (15.9%) |
| 4 | 238 (27.1%) |
| Lymph Node Status | |
| (+) Lymph Nodes | 64 (7.3%) |
| (−) Lymph Nodes | 817 (92.7%) |
| Distant Metastasis | |
| (+) Metastases | 23 (2.6%) |
| (−) Metastases | 858 (97.4%) |
| Surgical Margin | |
| Negative | 273 (30.9%) |
| Positive | 107 (12.0%) |
| Cannot Assess/ | 130 (14.8%) |
| No surgery | 371 (42.1%) |
| Hyams Grade | |
| 1 | 55 (6.3%) |
| 2 | 180 (20.4%) |
| 3 | 148 (16.9%) |
| 4 | 48 (5.4%) |
| Not stated | 450 (51.0%) |
| Treatment Type | |
| Extirp only | 154 (17.4%) |
| Extirp/RT | 229 (26.1%) |
| Extirp/C | 8 (0.9%) |
| Extirp/CRT | 119 (13.5%) |
| XRT | 240 (27.3%) |
| CRT | 113 (12.8%) |
| C | 18 (2.0%) |
Abbreviations: C, Chemotherapy; CI, confidence interval; CRT, Chemoradiotherapy; ENB, Esthesioneuroblastoma; NCI, National Cancer Institute; NI, not included; NR, not reportable; R, Radiotherapy; Ref, reference.